Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Community/Academic Research Collaboration Paves the Way for Improved Cancer Care

March 11th 2024

Gautam Jha, MD, and Emmanuel Antonarakis, MD, discuss the ins and outs of clinical trial partnerships between community and academic cancer centers.

Dr Shore on Key Clinical Trial Data in Biochemically Recurrent Prostate Cancer

March 11th 2024

Neal Shore, MD, FACS, discusses findings from clinical trials in patients with prostate cancer who experience biochemical recurrence.

Dr Hussain on Key Ongoing Clinical Trials in Metastatic Castrate-Resistant Prostate Cancer

March 11th 2024

Maha Hussain, MD, FACP, FASCO, discusses clinical trials evaluating therapeutics for patients with metastatic castrate-resistant prostate cancer.

Artificial Intelligence in Prostate Cancer Pathology: Friend or Foe?

March 9th 2024

Peter A. Humphrey, MD, PhD, presents on the standing of artificial intelligence in prostate cancer pathology.

Piecing the Puzzle Together: Treatment After Progression in Metastatic Castration-Resistant Prostate Cancer

March 9th 2024

The inter-tumoral complexity of metastatic castration-resistant prostate cancer poses a treatment challenge that may be tackled by examining clonal evolution.

Precision Medicine: Brief But Impactful in Prostate Cancer Management

March 8th 2024

The burst of translational research leading to PARP inhibitors in prostate cancer, along with imaging and diagnostic advances, has been a monumental evolution for the management of this disease.

Dr Childs on Treatment With Olaparib Plus Abiraterone in mCRPC

March 6th 2024

Dan S. Childs, MD, discusses treatment with olaparib and abiraterone in metastatic castration-resistant prostate cancer.

Community-Based Clinical Trial Enrollment Expands Access to Prostate Cancer Care

March 6th 2024

Gautam Jha, MD, and Emmanuel Antonarakis, MD, discuss enrollment to the ECLIPSE trial in community and academic cancer center settings.

Dr Shen on the Utility of ARX517 in mCRPC

March 4th 2024

John Shen, MD, discusses the utility of ARX517 in patients with metastatic castration-resistant prostate cancer.

Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

March 4th 2024

Our expert panel provide insightful discussion on the power of multidisciplinary expertise in advanced prostate cancer.

Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

March 4th 2024

Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistant prostate cancer.

New Clinical Practice Guideline Provides Overview on Salvage Therapy’s Role in Prostate Cancer

March 1st 2024

The American Urological Association has released their 2024 clinical practice guideline on salvage therapy for prostate cancer.

Dr Childs on Treatment Updates in mHSPC

March 1st 2024

Dan S. Childs, MD, discusses the evolution of the treatment armamentarium for patients with metastatic hormone-sensitive prostate cancer.

Dr Shore on Ongoing Research With Radioligand Therapy in nmCSPC

March 1st 2024

Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.

Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

February 26th 2024

This segment delves into targeting the androgen receptor pathway and conquering treatment resistance for potential breakthroughs in managing advanced prostate cancer.

Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

February 26th 2024

Expert perspectives on androgen receptor signaling and its role in fueling prostate cancer metastasis along with a whiteboarding animation depicting this process.

Swissmedic Accepts Marketing Authorization Application for Piflufolastat (18F) for Prostate Cancer

February 22nd 2024

Swissmedic has accepted for review a marketing authorization application seeking the approval of Piflufolastat (18F) for prostate cancer.

Dr Gong on the EMBARK Trial Investigating Enzalutamide in nmCSPC

February 20th 2024

Jun Gong, MD, discusses the significance of the phase 3 EMBARK study of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life

February 19th 2024

Drs. Shore & McKay discuss treatment selection for metastatic & castration-resistant prostate cancer, the current landscape, and key factors guiding personalized treatment decisions.

Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

February 19th 2024

GU medical oncologist Dr. Rana McKay and urologist Dr. Neal Shore explore how predictive biomarkers and genetic testing are informing risk assessment and guiding personalized treatment decisions in clinical practice